S932 Active Tuberculosis and Opportunistic Infections: Pooled Safety Analysis of Ustekinumab Through up to 5 Years Across All Approved Indications

Edward V. Loftus; Millie Long; Elyssa Ott; Christopher Gasink; Thomas Baker; Bridget Goodwin; Ye Miao; Subrata Ghosh

doi:10.14309/01.ajg.0000860368.55128.7d

S932 Active Tuberculosis and Opportunistic Infections: Pooled Safety Analysis of Ustekinumab Through up to 5 Years Across All Approved Indications

Edward V. Loftus
, Millie Long
, Elyssa Ott
, Christopher Gasink
, Thomas Baker
, Bridget Goodwin
, Ye Miao
, Subrata Ghosh

Mayo Clinic Rochester, MN
University of North Carolina at Chapel Hill
Janssen Scientific Affairs, LLC
Janssen Research & Development, LLC

Research output: Contribution to journal › Meeting abstract › peer-review

Original language	English
Pages (from-to)	e675
Journal	American Journal of Gastroenterology
Volume	117
DOIs	https://doi.org/10.14309/01.ajg.0000860368.55128.7d
Publication status	Published - Oct 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

Medicine
Ustekinumab
Concomitant
Internal medicine
Bristol-Myers
Psoriatic arthritis
Tuberculosis
Inflammatory bowel disease
Ulcerative colitis
Psoriasis
Surgery
Gastroenterology
Adalimumab
Disease
Dermatology
Pathology

Access to Document

10.14309/01.ajg.0000860368.55128.7d

Cite this

@article{35aa9356bd0f434ea9c252910ddbb47c,

title = "S932 Active Tuberculosis and Opportunistic Infections: Pooled Safety Analysis of Ustekinumab Through up to 5 Years Across All Approved Indications",

keywords = "Medicine, Ustekinumab, Concomitant, Internal medicine, Bristol-Myers, Psoriatic arthritis, Tuberculosis, Inflammatory bowel disease, Ulcerative colitis, Psoriasis, Surgery, Gastroenterology, Adalimumab, Disease, Dermatology, Pathology",

author = "Loftus, \{Edward V.\} and Millie Long and Elyssa Ott and Christopher Gasink and Thomas Baker and Bridget Goodwin and Ye Miao and Subrata Ghosh",

year = "2022",

month = oct,

doi = "10.14309/01.ajg.0000860368.55128.7d",

language = "English",

volume = "117",

pages = "e675",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Wolters Kluwer Health",

}

TY - JOUR

T1 - S932 Active Tuberculosis and Opportunistic Infections: Pooled Safety Analysis of Ustekinumab Through up to 5 Years Across All Approved Indications

AU - Loftus, Edward V.

AU - Long, Millie

AU - Ott, Elyssa

AU - Gasink, Christopher

AU - Baker, Thomas

AU - Goodwin, Bridget

AU - Miao, Ye

AU - Ghosh, Subrata

PY - 2022/10

Y1 - 2022/10

KW - Medicine

KW - Ustekinumab

KW - Concomitant

KW - Internal medicine

KW - Bristol-Myers

KW - Psoriatic arthritis

KW - Tuberculosis

KW - Inflammatory bowel disease

KW - Ulcerative colitis

KW - Psoriasis

KW - Surgery

KW - Gastroenterology

KW - Adalimumab

KW - Disease

KW - Dermatology

KW - Pathology

UR - https://openalex.org/W4316086191

U2 - 10.14309/01.ajg.0000860368.55128.7d

DO - 10.14309/01.ajg.0000860368.55128.7d

M3 - Meeting abstract

SN - 0002-9270

VL - 117

SP - e675

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

ER -

S932 Active Tuberculosis and Opportunistic Infections: Pooled Safety Analysis of Ustekinumab Through up to 5 Years Across All Approved Indications

UN SDGs

Keywords

Access to Document

Other files and links

Cite this